Reply to the Letter by Derendorf: Clinical Trials and Dipyridamole Formulation Selection

73 3 Antithrombotic Trialists’ Collaboration: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71–86. 4 Algra A, van Gijn J, Koudstaal PJ: Secondary prevention after cerebral ischaemia of presumed arterial origin: is aspirin still the touchstone? J Neurol Neurosurg Psychiatry 1999; 66: 557–559. 5 European Stroke Prevention Study 2: efficacy and safety data. J Neurol Sci 1997; 151(suppl):S1–S77. 6 Dresse A, Chevolet C, Delapierre D, Masset H, Weisenberger H, Bozler G, Heinzel G: Pharmacokinetics of oral dipyridamole (Persantine) and its effect on platelet adenosine uptake in man. Eur J Clin Pharmacol 1982; 23: 229–234. 7 Derendorf H, Vander Maelen CP, Brickl RS, MacGregor TR, Eisert W: Dipyridamole bioavailability in subjects with reduced gastric acidity. J Clin Pharmacol 2005; 45: 845–850.